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Summary 
 Optical coherence tomography (OCT) has shown thinning of the retinal nerve 
fibre layer (RNFL) and total macular volume (TMV) in multiple sclerosis (MS) 
patients. Measures of retinal atrophy are associated with the brain parenchymal 
fraction (BPF) assessed by MRI. However, in MS, data on the relation of OCT 
measures and grey and white matter volumes are contradictory. 
We performed a cross-sectional study with a statistically pre-defined endpoint to test 
our hypothesis that OCT measures of neuro-axonal degeneration are related to 
global and partial brain atrophy in early forms of MS. 
44 patients with clinically isolated syndrome (CIS, n=10) or relapsing remitting MS 
(RRMS, n=34) (mean disease duration=3.2 years, median EDSS=1.5) were enrolled 
in the study. Peripapillary- and volumetric OCT scans of the macula were performed 
using latest spectral-domain OCT technology. BPF as well as white and grey matter 
fractions (WMF/GMF) were assessed by 1.5 T MRI scans. Generalized estimating 
equation models (GEE) adjusted for age and linear regression statistics were used to 
assess the association between OCT and MRI measures.  
RNFL thickness, TMV and age were significantly associated with BPF. RNFL 
thickness, and TMV independently predicted WMF (p=0.003 and p=0.032) but not 
GMF (p=0.717 and p=0.357) when corrected for age. In contrast, age was strongly 
associated with GMF (p<0.001) but not WMF. 
Our study suggests that, in early MS, OCT measures of retinal atrophy indicate 
white- but not grey matter damage as assessed by MRI. It further substantiates the 
association of retinal thinning and brain tissue loss in MS. 
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Introduction 
 
Demyelination caused by T cell-induced autoimmune inflammation has long 
been considered the primary hallmark of multiple sclerosis (MS). There is, however, 
increasing evidence that axonal damage and neuronal loss contribute significantly to 
irreversible functional deficits in MS [1]. Axonal damage occurs within inflammatory 
lesions [2-4] but also remote from sites of autoimmune inflammation [5,6]. Of note, 
axonal degeneration starts very early in the disease course and has been found in 
both active and inactive plaques [4].  
Magnetic resonance imaging (MRI) is the best established structural measure to 
capture disease activity in MS. Conventional MRI sequences are sensitive for the 
monitoring of inflammatory MS lesions. In addition, the quantification of T2 lesions at 
the time of diagnosis has limited predictive value with respect to future disability 
evolution [7]. However, the association of MRI markers of inflammation and disability 
progression throughout the further disease course is weak [8,9]. In contrast, MRI 
measures of degeneration and atrophy appear to correlate better with disability 
evolution. The brain parenchymal fraction (BPF) or, conversely, ventricular 
enlargement, are widely used MRI outcomes to depict global brain atrophy in MS 
[9,10]. An inverse relation between BPF and disability progression has repeatedly 
been demonstrated [11,12]. Further, MRI-based stratification by the amount of 
inflammatory lesions and the extent of both global and focal brain atrophy during 
consecutive, monthly MRI scans has been used to dissect disease heterogeneity in 
MS [13]. Interestingly, disease progression over time was most pronounced in the 
subgroup with both high inflammation and degenerative changes [13]. Assessing 
atrophy parameters employs three-dimensional MRI sequences and segmentation 
 
 
algorithms, that are, however, time consuming and not easily accessible in routine 
clinical practice. Furthermore, a number of confounding factors like inflammatory 
edema, hydration status, anti-inflammatory treatments and age have been shown to 
impact on the results of such atrophy measures by MRI [14, 15]. 
Optical coherence tomography (OCT) studies have consistently shown thinning of 
the retinal nerve fibre layer (RNFL) and total macular volume (TMV) in MS, both in 
patients with and without a history of acute optic neuritis (ON) [16]. Based on these 
data, the RNFL thickness (RNFLT) and TMV have been proposed as potential 
surrogate outcome measures of neuro-axonal degeneration in MS [14]. Recent 
studies suggest that OCT measures of retinal degeneration correlate with MRI 
measures of brain tissue loss [17-21].  As a limitation of all these studies, time 
domain OCT (TD-OCT) has been used as opposed to the more advanced and more 
accurate spectral domain OCT technique (SD-OCT), with faster data acquisition, 
greater reliability and higher resolution [17, 22]. Moreover, these previous studies 
were either carried out in small- [20, 23], or heterogeneous groups of patients [17, 
18] or rather late in the disease course [17, 23].  
There is little doubt that neurodegenerative processes become more and more 
prominent during more advanced disease stages like secondary progressive MS 
(SPMS). However, as axonal degeneration is already detectable as early as at the 
primary manifestation of the disease, the so-called clinically isolated syndrome (CIS), 
there is a need to investigate the relationship between OCT measures of retinal 
axonal degeneration and MRI measures of brain tissue loss early in the disease 
course [4]. 
We therefore designed a highly powered (95%), cross-sectional study with a 
statistically pre-defined endpoint applying latest OCT technology (spectral domain 
 
 
Spectralis® OCT) to test the hypothesis, that OCT measures of neuronal and axonal 
degeneration are related to MRI measures of global brain atrophy (BPF) and 
regional volumes (grey and white matter fraction) already at very early disease 
stages.  
Patients and Methods 
 
Patients 
Forty-four patients with clinically isolated syndrome suggestive of MS (CIS 
(n=10)) or an established diagnosis of RRMS (n=34) according to the 2005 revised 
McDonald criteria [24] were prospectively enrolled at the MS Outpatient- and Day 
Clinic at the Institute for Neuroimmunology and Clinical Multiple Sclerosis Research 
(inims), University Medical Center Hamburg Eppendorf, Hamburg, Germany. All 
patients met the following criteria: age between 18 and 60 years, disease duration 
(as defined by time since first reported symptoms) not exceeding ten years, no acute 
relapse and no systemic steroid treatment within 30 days prior to study entry. 
Patients had to be off immunomodulatory treatment with interferons for at least 90 
days before enrolment. Treatment with the monoclonal antibody natalizumab or 
glatirameracetate had to be stopped 6 months before study entry. Patients were 
scanned twice by MRI, at baseline and after an interval of six to twelve months. 
Patients with a CIS were only included if they showed one or more lesions in at least 
two out of four anatomical regions defined by the Barkhof criteria for dissemination in 
space. Neurological disability was assessed by a trained neurologist, blinded for MRI 
and OCT results, using the Expanded Disability Status Scale (EDSS) [25] and the 
Multiple Sclerosis Functional Composite (MSFC) [26]. Visual acuity was determined 
 
 
using Snellen charts. Patients did not suffer from any metabolic, ophthalmological or 
neurological disorder other than MS by history. Patients with severe myopia 
(refraction error ≥ 6.0) were excluded from the study. Written informed consent was 
obtained from all patients. The study was approved by the Ethical Committee of the 
Board of Physicians in the State of Hamburg. 
 
Methods 
Magnetic Resonance Imaging 
Brain MRIs were performed on a 1.5 Tesla scanner (Magnetom Sonata, Siemens, 
Erlangen, Germany) with a standard head coil. It consisted of a multiplanar 
reconstructed T1-weighted rapid gradient echo sequence (MPRAGE, TE: 3.82 ms, 
TR 1900 ms, slice thickness: 1 mm, FOV: 256 mm), an axial spin echo proton 
density (PD)-weighted, a T2-weighted sequence (PD TE: 33 ms, T2 TE: 116 ms, TR 
3540 ms, slice thickness: 5 mm, FOV: 230 mm) and a post-gadolinium T1-weighted 
sequence (TE: 10 ms, TR 500 ms, slice thickness: 5 mm, FOV: 230 mm).   
 
MRI data analysis 
All MRI scans were evaluated by two independent and experienced raters blinded for 
the clinical status of the patients.  T2/PD-, T1 and T1Gd+ lesion volumes were 
measured with JIM Version 5.0 (Xinapse Systems, Ardwincle, UK). Hyperintense 
lesions were marked on the PD scans and controlled by the T2 sequence. T2 lesions 
were marked when they appeared hyperintense in PD and T2. The rater had to 
exclude partial volume effects, perivascular spaces and other lesion-like 
hyperintensities. Confluent lesions were counted as one lesion. T1 black holes were 
defined as areas of signal hypointensity on contrast-enhanced T1 weighted images 
 
 
with T2 hyperintense correlates. The intensity for black holes was defined as 
intermediate between cortical grey matter and CSF.  T1 black hole volumes of the 
second scan were used to determine the black hole fraction (BHFr = hypointense 
lesion volume [T1vol] x 100 / hyperintense lesion volume [PDvol] - volume of 
enhancing lesions [T1Gd+]) as a measure of focal tissue destruction.  
Total and segmented intracranial volumes of grey matter, white matter and CSF of 
both scans were calculated using FAST v4.1, part of FSL 4.1.4 on MPRAGE images 
[27,28]. In order to avoid detection of T1 hypointense lesions as grey matter, T1 
lesion masks were implemented into the MPR sequence, using individually averaged 
normal appearing white matter (NAWM) values before brain tissue volume 
segmentation. Since FSL generates absolute grey and white matter volumes for 
each patient that make group comparisons difficult, we calculated fractions 
analogous to the standard brain parenchymal fraction (BPF) calculations. Whole 
brain parenchymal and segmented volumes were calculated as follows: BPF [%] = 
grey matter volume (GMV) plus white matter volume (WMV) x 100 / total intracranial 
volume (TIV), where TIV=GMV+WMV+CSF volume. Grey matter fraction (GMF [%] = 
GMV x 100 / TIV) and white matter fraction (WMF [%] = WMV x 100 / TIV) were 
calculated separately. 
 
Spectral Domain Optical Coherence Tomography 
Retinal measures of RNFL and total macular volume (TMV) were performed on a 
SD-OCT device (Heidelberg-Spectralis® SD-OCT, Heidelberg Engineering, 
Heidelberg, Germany, Spectralis software version 5.2.4.0, Eye Explorer software 
1.6.2.0). This device incorporates a confocal scanning laser ophthalmoscope 
(CSLO) enabling it to perform active eye-tracking (TrueTrac™). Active eye-tracking is 
 
 
used to adapt the software to eye movements and allows co-registration of the 
depth-scan with the CSLO fundus image.For RNFL, two 3.4 mm (12º) circular scans 
around the optic nerve head (ONH) consisting of 768 A-scans were acquired for 
each patient using the standard protocol by a qualified operator. The scan was 
performed in a darkened room and pupils were not pharmacologically dilated [30]. 
Quality of the OCT scans was rated by three independent readers. OCTs were 
excluded when all three raters rejected the scan for one or more of the following 
reasons: alignment- or algorithm failure, poor signal strength (<15), in cases, where 
the fundus was poorly illuminated, or if retinal pathology was detectable that would 
potentially impair RNFL readings. RNFL thickness (RNFLT) was calculated by the 
device’s segmentation algorithm. For TMV, the built-in Fast Macular Volume protocol 
consisting of … lines vertically crossing the macula was used. 
 
Statistical Analysis  
The study was a prospective observational study with a primary endpoint defined by 
a regression approach with BPF as target and RNFLT, history of optic neuritis and 
age as independent variables. We hypothesized a significant association of RNFLT 
with BPF when correcting for age, tested for by using Generalized Estimating 
Equations accounting for intra-patient inter-eye dependencies. Generalized 
Estimating Equations models (GEE) accounting for intra-patient inter-eye 
dependencies were used to assess the association between OCT and MRI using 
OCT parameters as independent- and MRI parameters as dependent variables and 
age as covariate. Additionally, solely for reasons of comparability with previously 
published studies, minimum RNFLT and minimum TMV were calculated as the lower 
respective value from each patient’s eyes [17, 18]. E.g. if the right eye of a patient 
 
 
showed a lower mean RNFL  thickness than the left eye, the right eye’s RNFL would 
have entered the analysis as this patient’s minimum RNFL. Correlations between 
these minimum OCT values and MRI parameters were assessed using Spearman’s 
Rho analysis. R2 was calculated from linear regression models using MRI 
parameters as dependent- and OCT parameters as independent variables and 
correcting for age. 
All statistical analyses were performed using IBM SPSS version 19 (IBM, Somers, 
NY, USA). A threshold of p < 0.05 was considered significant. All tests besides the 
primary endpoint should be understood as exploratory data analysis, in that no 
previous power calculation and adjustments for multiple testing were performed. 
 
 
Sample size calculation 
Sample size was calculated using G*Power 3.1.2 [30]. The sample size was 
calculated based on the results of the study by Gordon-Lipkin and colleagues [17]. 
Since no sample size calculation is available for GEE models applied here, sample 
size calculation was based on linear multiple regression models using the random 
model that supposes both target and predictor variables as random and should thus 
deliver a feasible estimation of the sample size required for GEE. A squared multiple 
correlation R2 of 0.43 for RNFLT plus age and history of optic neuritis on BPF as 
previously reported [17] would be detected with 95% power (alpha=0.05, two-sided, 
k=3 predictors) for n=43 patients.  
 
 
 
Results 
 
Patient and clinical characteristics 
A total of forty-four patients were enrolled in this study to achieve a power of 
greater than 95%. The demographic data are summarized in table 1. Three RNFLT 
measurements were excluded by independent raters due to algorithm failure or poor 
signal strength. Nine TMV measurements were excluded from analysis due to poor 
signal strength or algorithm misalignment. Table 2 summarises the OCT data.  
All MRI data sets could be analysed (table 2). The BHFr could be calculated from a 
total of 28 patients with a T2 lesion volume of >1ml. 22 eyes (25.9%) had a history of 
ON, 63 eyes (74.1%) did not. Minimum RNFLT correlated with age (Spearman’s 
Rho=-0.440, p=0.003), and with minimum TMV (Spearman’s Rho=-0.363, p=0.017) 
and BPF (Spearman’s Rho=0.453, p=0.002). There were no correlations with the 
EDSS (minimum RNFLT p=0.557, minimum TMV p=0.312, BPF p=0.079) or disease 
duration (minimum RNFLT p=0.327, minimum TMV p=0.749, BPF p=0.718). The 
black hole fraction did not correlate with age (p=0.880) or EDSS (p=0.238). However, 
there was a correlation with disease duration (Rho=0.401, p=0.035) (all Spearman’s 
Rho analyses). 
 
Association between RNFLT, TMV and MRI  
The results from GEE with MRI parameters as dependent variable, OCT parameters 
as independent variables and age and history of ON as covariate are given in table 
3. The primary endpoint (RNFLT association with BPF with covariates age and 
history of ON) was significant (p=0.005). In an exploratory analysis using segmented 
volumes (WMF and GMF) as parameters for axonal and neuronal degeneration, 
 
 
respectively, and the BHFr as parameter for focal tissue destruction, we observed an 
association between RNFLT and WMF as well as GMF. However, GEE analysis 
proved the association with GMF rather to be  based on age-related effects, whereas 
the association between RNFLT and WMF appears to derive from true RNFLT 
effects (Table 3). Interestingly, there was no association between BHFr, reflecting 
focal atrophy or rather destructive focal lesions, and RNFLT in this model. Results 
from comparisons of TMV with MRI parameters were in line with those described for 
RNFLT (Table 3). GMV showed a similar association to age only, whereas the 
association from WMV with RNFLT was lost (not shown). There was no association 
between T2 lesion volume and black hole volume with either RNFLT or TMV (not 
shown). To rule out possible gender effects, we re-calculated each analysis, this time 
incorporating sex as a covariate, resulting in no change of significance levels (data 
not shown). 
 
Minimum RNFLT and minimum TMV association with MRI  
Next, we analyzed associations between OCT and MRI parameters using linear 
regression models with MRI parameters as dependent variables and OCT measures 
(minimum RNFLT; minimum TMV) as independent variables and age as covariate. 
Although these models do not take inter-eye dependencies into account, they should 
give an appropriate estimate of effect sizes and correlation in a diagnostic setting 
when interpreted carefully in combination with results from GEEs above. 
Furthermore, taking these data allows comparison of our results with data that had 
previously been published by others [17]. Results are summarised in table 3. Figure 
1 shows results from linear regression on the association of minimum RNFLT with 
MRI parameters (BPF, GMF and WMF) not corrected for age. Taken together, the 
 
 
linear regression models support the primary endpoint with an adjusted R2 (minimum 
RNFLT and age) of 0.501 as well as – analogous to the GEE above - the 
associations between GMF and age, and between WMF and minimum RNFLT. 
Discussion 
 
Here we show that measures of retinal atrophy assessed by latest spectral 
domain OCT technology and age are inversely associated with brain MRI white- and 
grey matter damage in early forms of MS. Both RNFLT and TMV significantly 
explained the variance of WMF, whereas age did not. In contrast, age, but not 
RNFLT or TMV significantly predicted the variability in GMF. Our work confirms and 
extends the strong association of RNFLT and BPF, a measure of global brain 
atrophy, previously described by others [3, 17, 18, 20, 23, 31] in a highly 
homogeneous cohort of untreated MS patients with mostly early disease. 
Moreover, our study assesses MRI/OCT associations with high-resolution spectral 
domain OCT and in a cohort of untreated CIS and early RRMS patients by a 
statistically pre-defined primary endpoint based on sample size calculations derived 
from findings of a previous report [17]. The most important observation of the present 
study is the independent association of OCT measures of retinal atrophy with MRI-
derived WMF, but not GMF or BHFr when corrected for age and a history of optic 
neuritis, a finding that consistently resulted from both statistical models applied (GEE 
and linear regression models with minimum RNFL and TMV). Our data – at least in 
part - contradict observations from previous publications, which yielded conflicting 
results [4, 17-20, 23].  A first study investigating the association between OCT 
measures and MRI brain atrophy in RRMS, secondary- and primary progressive MS 
 
 
patients with higher EDSS and longer disease duration than our patients observed a 
significant correlation of minimum RNFLT, but not of TMV with BPF when correcting 
for age, and solely age-dependency of white matter volume (WMV) [17]. In contrast, 
grey matter volume (GMV) was neither associated with RNFLT nor age. A second 
study in a Spanish cohort by Sepulcre and colleagues – again with a heterogeneous 
cohort including CIS, RRMS, secondary- and primary progressive MS patients  – 
reported significant correlations of average RNFLT with both WMV and GMV, 
whereas TMV was not investigated [18]. Siger et al. found a correlation of average 
RNFLT (mean from both eyes) only with GMF but not WMF in a subgroup of RRMS 
patients without a history of optic neuritis. However, the authors did not correct for 
age and examined a cohort with higher disease duration and EDSS when compared 
to the group of CIS and RRMS patients studied here [31]. Interestingly, no correlation 
between OCT and MRI measures was found by the same investigators in a 
subgroup of RRMS patients with a history of optic neuritis. Comparability between 
these results and ours is limited for several reasons: 1. different patient selection 
criteria with inclusion of heterogeneous disease courses, 2. heterogeneity with 
respect to disability and disease duration, 3. methodological differences in post-
processing procedures for BPF and partial brain volume measurements, 4. 
application of time domain versus spectral domain OCT technology, 5. 
heterogeneous sample sizes, and 6. inhomogeneous retinal measures (mean versus 
minimum RNFLT) entering multiple regression analysis and statistical approaches. 
These differences may also explain the conflicting results regarding the association 
of OCT measures and GM atrophy, for which some authors have found a relationship 
[18, 20, 31] whereas others did not [17, 23].  
Also, in our early MS cohort, we do not find a correlation of either OCT or MRI 
 
 
atrophy measures with the EDSS which instead has been described in some but not 
all previous studies [16]. A possible explanation for this discrepancy might well be the 
overall very low EDSS scores in the patients described here with a median of 1.5 
whereas higher EDSS scores are scarcely represented.   
Our observation of a consistent association of both TMV and RNFL- assessed by the 
novel spectral domain OCT - with WMF but not GMF raises interesting questions 
regarding the underlying mechanisms and time course of MS-associated brain 
damage and injury to retinal axons, which are anatomically linked via the optic nerve. 
Thinning of the RNFL is considered to reflect damage to axons emerging from the 
retinal ganglion cells, thus CNS axons. Decrease of WMF may be the consequence 
of both demyelination and axonal loss, while loss of GM is believed to reflect 
damage to neuronal cell bodies. It is intriguing to hypothesize that in this early cohort 
with short disease duration in the majority of patients and low EDSS, OCT measures 
- irrespective of direct involvement of the optic nerve and the anterior visual pathway 
in MS pathology - partially also reflect more diffuse white matter damage remote 
from these sites. Further, we speculate that this white matter damage precedes later 
damage of neuronal cell bodies in the grey matter. In MS, degeneration detected by 
OCT measures of retinal atrophy might indirectly be associated with the extent of 
axonal damage in the brain compartment or be mediated by mechanisms like 
retrograde trans-synaptic degeneration, in case of lesions inflicting the posterior 
visual tract [6]. On the other hand, grey matter atrophy in the cohort reported here is 
predominantly driven by age and not associated with axonal degeneration depicted 
by OCT and WMF. Conceivably, a re-assessment of our patients at a later stage of 
their disease course might unravel an association of OCT measures also with grey 
matter damage, as with disease progression and increasing neuronal damage the 
 
 
influence of the disease in relation to age on grey matter atrophy might prevail. Such 
a concept would suggest that, in early disease, autoimmune inflammation is mainly 
associated with demyelination, partial remyelination and to some extent axonal loss. 
When disease progresses secondary Wallerian degeneration and eventually loss of 
neuronal cell bodies may lead to disease- rather than age-related loss of grey matter. 
This might in part also explain the discrepancies with the data from other studies 
performed in patients that had advanced further into the disease and presented with 
a more progressive MS phenotype [17, 18]. 
A limitation of our study is the lack of a control group. However, we believe this 
highly unlikely to have a confounding effect on our data. Not only does one not 
expect significant thinning of the RNFL or volumetric measures in a group of healthy 
controls without ophthalmological comorbidity, nor did previous studies that have 
addressed this aspect by means of OCT and MRI in MS patients and controls [17, 
18] find such loss or association in the respective control group. 
RNFL thinning might only depict part of the overall retinal pathology in MS, and due 
to current methodological limitations, OCT measures might miss degeneration of 
layers below the level of retinal ganglion cell axons, like the ganglion cell- or inner 
and outer nuclear layers. Recent post-mortem and OCT studies suggest that a 
primary retinal pathology beyond damage to the RNFL may exist in a subgroup of 
MS or possibly also in the general population [32-34]. Our study suggests that, as 
soon as OCT segmentation algorithms become available to systematically identify 
MS phenotypes with an involvement of retinal cell bodies, MRI studies on grey 
matter pathology should be integrated. 
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Figure Legends 
Figure 1 
Association of RNFLT with BPF (A) and WMF (B). Solid lines are derived from a 
linear regression analysis with minimum RNFLT as independent and the respective 
MRI parameter as dependent variable. R2 from these linear models are given in the 
upper right corner of each figure section. Dashed lines represent 95% confidence 
intervals. Abbreviations: RNFLT = retinal nerve fibre layer thickness, BPF[%] = 
brain parenchymal fraction, WMF[%] = white matter fraction. 
  
 
 
Table 1.  Patient demographics and clinical data 
   
      
Subjects n 44 
 
Gender Male (%) 9 (20.5%) 
 Female (%) 35 (79.5%) 
 
Age [years] Mean (SD) 41.4 (8.8) 
 Min - Max 24 - 60 
    
Diagnosis RRMS (%) 34 (77.3%) 
 CIS (%) 10 (22.7%) 
    
Disease duration [years] Mean (SD) 3.2 (2.7) 
 Min - Max 0.1 - 8.9 
 
EDSS Median 1.5 
 Min - Max 0.0 - 4.5 
    
Eyes n 85 
 
History of Optic Neuritis No (%) 63 (74.1%) 
 Yes (%) 22 (25.9%) 
 
Visual Acuity (high contrast) Mean (SD) 1.03 (0.14) 
 Min - Max 0.66 - 1.25 
   
 
EDSS= Expanded Disability Status Scale; RRMS=Relapsing remitting multiple sclerosis; 
CIS=Clinically isolated syndrome 
  
 
 
Table 2. OCT and MRI data 
     
  Mean SD Min Max 
OCT      
RNFLT Average [µm] 92,5 10,2 63 112 
      
RNFLT Temporal Quadrant [µm] 67,5 15,2 33 111 
RNFLT Superior Quadrant [µm] 108,1 14,5 74 145 
RNFLT Inferior Quadrant [µm] 121,6 16,3 80 162 
RNFLT Nasal Quadrant [µm] 72,1 13,3 47 117 
      
Macular Volume TMV [mm³] 8,34 0,39 7,58 9,14 
      
MRI         
T1 black hole volume (BHV) [ml] 
            
0,51 1,44 0 8,2 
T2 lesion volume (T2V) [ml] 2,55 3,18 0,06 15,42 
T1 Gd enhancing lesion volume 
(GEV) [ml] 0,07 0,14 0 0,62 
      
Black hole fraction (BHFr=BHV/T2V) 13% 16% 0% 55% 
      
CSF [ml] 399.899 56.171 301.433 569.291 
GMV [ml] 839.906 76.720 693.391 1.011.498 
WMV [ml] 577.893 64.175 483.454 699.297 
      
BPF 
((GMV+WMV)/(GMV+WMV+CSF)) 
78,0% 2,1% 73,7% 82,3% 
GMF ((GMV)/(GMV+WMV+CSF)) 46,0% 2,0% 43,0% 49,0% 
WMF ((WMV)/(GMV+WMV+CSF)) 32,0% 1,0% 29,0% 35,0% 
 
RNFLT=Retinal nerve fibre layer thickness; PMB=Papillomacular bundle; TMV=Total macular volume; 
BHFr=Black hole fraction; CSF=Cerebrospinal fluid; GMV=Grey matter volume; WMV=White matter 
volume; BPF=Brain parenchymal fraction; GMF=Grey matter fraction; WMF=White matter fraction 
  
 
 
Table 3. GEE and linear regression models for predicting MRI measures from OCT data 
 
GEE=Generalized Estimating Equation Models; BPF=Brain parenchymal fraction; GMF=Grey matter 
fraction; WMF=White matter fraction; BHFr=Black hole fraction; RNFLT=Retinal nerve fibre layer 
thickness; TMV=Total macular volume 
  
     
  BPF GMF WMF BHFr 
     
LR Adjusted R2 for age + minimum 
RNFLT 0.501 0.353 0.395 0.114 
GEE p-value for age 
 
<0.001 <0.001 0.429 0.818 
LR R2 change for age (p-value) 0.265 (<0.001) 0.374 (<0.001) 0.012 (0.499) 0.003 (0.798) 
GEE p-value for RNFLT 0.005 0.717 0.003 0.994 
LR R2 change for minimum RNFLT (p-
value) 0.237 (<0.001) 0.026 (0.211) 0.319 (<0.001) 0.012 (0.621) 
     
LR Adjusted R2 for age + minimum 
TMV 0.374 0.334 0.220 0.066 
GEE p-value for age <0.001 <0.001 0.442 0.578 
LR R2 change for age (p-value) 0.260 (<0.001) 0.366 (<0.001) 0.012 (0.502) 0.017 (0.547) 
GEE p-value for TMV 0.034 0.357 0.032 0.616 
LR R2 change for minimum TMV (p-
value) 0.127 (0.008) 0.017 (0.322) 0.158 (0.008) 0.039 (0.372) 
 
 
 
